Age (older) | Gender (male) | Deprivation (more) | Ethnicity | |
---|---|---|---|---|
Overall | ||||
All diseases* | p<0.001 OR 0.87 (0.86–0.88) | Black: p=0.00 075 OR 0.61 (0.46–0.81) | ||
Disease where guidelines indicate treatment with high-cost drug on most occasions | ||||
1. Aspergillosis | p=0.023 OR 1.06 (1.01–1.11) | |||
2. Candidosis | p<0.0005 OR 0.85 (0.83–0.88) | p<0.0005 OR 0.9 (0.87–0.94) | ||
Disease where guidelines indicate prophylaxis on most occasions | ||||
4. Stem cell/bone marrow transplant in haematological malignancy | p<0.0005 OR 0.82 (0.74–0.89) | p=0.00 312 OR 1.13 (1.04–1.23) | ||
7. Lung transplant | p<0.0002 OR 0.38 (0.23–0.64) | p=0.026 OR 0.9 (0.82–0.99) | ||
Disease where guidelines indicate prophylaxis depends on the risk factors present on presentation | ||||
5. Haematological malignancy | p<0.0005 OR 0.82 (0.81–0.83) | Black: p=0.005 OR 0.62 (0.841–0.86); mixed: p=0.005; OR 2.44 (1.29–4.52) | ||
8. Other solid organ transplant | ||||
9. Solid tumour | p=0.02 OR 1.06 (1.01–1.11) | p<0.0005 OR 1.99 (1.56–2.55) | ||
11. Immunosystem disease | p=0.04 OR 0.8 (0.65–0.98) | |||
12. Acute peritonitis | ||||
13. Abdominal surgery |
*Disease groups were also included in the model. These results therefore indicate the association between patient factors and the use of a high-cost antifungal independent of disease group.